|
Gender
|
|
Male
|
3 (2.8)
|
1.000
|
|
Female
|
4 (2.6)
|
|
Age (years) at HAART initiation
|
|
< 35
|
2 (2.4)
|
1.000
|
|
> 35
|
5 (2.8)
|
|
Age (years) at 36 months median time of HAART follow up
|
|
< 39
|
3 (2.1)
|
0.706
|
|
> 39
|
4 (3.4)
|
|
Residence
|
|
Rural
|
1 (2.0)
|
1.000
|
|
Urban
|
6 (2.8)
|
|
Chronic non-communicable diseasesa
|
|
Yes
|
0 (0)
|
1.000
|
|
No
|
72.8)
|
|
TB co-infection
|
|
Yes
|
4 (9.3)
|
0.016
|
|
No
|
3 (1.4)
|
|
History of Opportunistic Infections (other than TB)b
|
|
Yes
|
3 (2.1)
|
0.704
|
|
No
|
4 (3.4)
|
|
HBV co-infection
|
|
Yes
|
2 (18.2)
|
0.05
|
|
No
|
3 (2.8)
|
|
HCV co-infection
|
|
Yes
|
1 (50.0)
|
0.062
|
|
No
|
1 (1.6)
|
|
Adherence to treatment
|
|
Poor/fair
|
2 (11.1)
|
0.08
|
|
Good
|
5 (2.1)
|
|
WHO clinical stage at baseline
|
|
I and II
|
0 (0.0)
| |
|
III and IV
|
7 (5.1)
| |
|
CD4+ count (cell/μl) at baseline
|
|
< 100
|
5 (6.5)
|
0.026
|
|
> 100
|
2 (1.1)
|
|
Regimen given
|
|
TDF basedc
|
7 (3.6)
| |
|
AZT basedd
|
0 (0)
| |
